Header

Shanghai Aifei officially became the general agent of IONpath in China

埃飞电子  2022-05-31

Shanghai Aifei Electronic Technology Co., Ltd. and IONpath signed an exclusive agency agreement in China, officially becoming the exclusive agent of the MIBIscope system of IONpath in the United States




The MIBIscope platform jointly developed by IONpath and Stanford University can help solve the most complex problems in the field of immuno-oncology. MIBIscope can simultaneously analyze at least forty proteins on a single slide with the reproducibility required for large clinical studies. Ultra-high resolution imaging. Recently, Shanghai Aifei Electronic Technology Co., Ltd. and IONpath signed an exclusive agency agreement in China, officially becoming the exclusive agent of the MIBIscope system of IONpath in the United States, responsible for the marketing, technical support and after-sales service of the product, let us join hands Together to lead a transformative step forward in tissue imaging




About IONpath, Inc. and IONpath Research Services


IONpath, Inc. is a pioneer in high-definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate medical discovery and improve human health. IONpath's MIBI (Multiplexed Ion Beam Imaging) platform goes beyond the limitations of traditional immunohistochemistry (IHC), enabling a deeper understanding of the tissue microenvironment through highly multiplexed quantitative single-cell analysis. Leveraging MIBI technology and the expertise of world-class pathology and data science teams, IONpath provides actionable access to translational and clinical researchers at leading pharmaceutical, biotechnology and research organizations in immuno-oncology, immunology, neuroscience and infectious disease research insights. IONpath's MIBI (Multiple Ion Beam Imaging) technology fulfills the promise of spatial proteomics by providing translational medicine researchers with unprecedented insights. Through highly multiplexed, quantitative protein imaging with unmatched sensitivity and true subcellular resolution down to 280 nm, only MIBI technology can provide actionable insight into individual cells in complex tissue microenvironments, and clinical research required throughput and reproducibility



footer